Boehringer Ingelheim's Zongertinib NDA219042 Receives AP Status from FDA
The FDA has granted an Approval Pending (AP) status for Boehringer Ingelheim's supplemental NDA for Zongertinib.
Asset / Drug
Drug and asset intelligence for Zongertinib with 2 indexed intelligence signals across regulatory, clinical, competitive, and market developments.
No catalysts indexed for this entity yet.
No catalysts indexed for this entity yet.
No related entities indexed yet.
Newsletter
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.